NZ594844A - Prion-specific peptoid reagents - Google Patents

Prion-specific peptoid reagents

Info

Publication number
NZ594844A
NZ594844A NZ594844A NZ59484406A NZ594844A NZ 594844 A NZ594844 A NZ 594844A NZ 594844 A NZ594844 A NZ 594844A NZ 59484406 A NZ59484406 A NZ 59484406A NZ 594844 A NZ594844 A NZ 594844A
Authority
NZ
New Zealand
Prior art keywords
glycine
sequence
replaced
substituted
residues
Prior art date
Application number
NZ594844A
Other languages
English (en)
Inventor
David Peretez
Michael D Connolly
Ronald Zuckermann
Man Gao
Robert M Shimizu
Gulliver Timoteo
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NZ594844A publication Critical patent/NZ594844A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
NZ594844A 2005-09-09 2006-09-08 Prion-specific peptoid reagents NZ594844A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US71576105P 2005-09-09 2005-09-09
US72668605P 2005-10-14 2005-10-14
US75893406P 2006-01-13 2006-01-13
PCT/US2006/035226 WO2007030804A1 (en) 2005-09-09 2006-09-08 Prion-specific peptoid reagents

Publications (1)

Publication Number Publication Date
NZ594844A true NZ594844A (en) 2013-04-26

Family

ID=37651167

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ594844A NZ594844A (en) 2005-09-09 2006-09-08 Prion-specific peptoid reagents
NZ566020A NZ566020A (en) 2005-09-09 2006-09-08 Prion-specific peptoid reagents

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ566020A NZ566020A (en) 2005-09-09 2006-09-08 Prion-specific peptoid reagents

Country Status (14)

Country Link
US (2) US7834144B2 (enExample)
EP (2) EP2383281A3 (enExample)
JP (2) JP5209477B2 (enExample)
KR (1) KR20080048527A (enExample)
CN (1) CN101356186A (enExample)
AU (1) AU2006287299B2 (enExample)
BR (1) BRPI0615618A2 (enExample)
CA (1) CA2621767A1 (enExample)
DK (1) DK1931695T3 (enExample)
ES (1) ES2404940T3 (enExample)
IL (1) IL189992A0 (enExample)
NZ (2) NZ594844A (enExample)
WO (1) WO2007030804A1 (enExample)
ZA (1) ZA200802186B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2006076497A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
US7834144B2 (en) 2005-09-09 2010-11-16 Novartis Ag Prion-specific peptoid reagents
FR2892820B1 (fr) * 2005-11-03 2008-02-01 Diagast Soc Par Actions Simpli Procede magnetique d'immunodiagnostic pour la mise en evidence de complexe anticorps/antigene, en particulier de groupe sanguin
US9260476B2 (en) 2007-02-23 2016-02-16 The Research Foundation For The State University Of New York RNA targeting compounds and methods for making and using same
US9150612B2 (en) * 2007-02-23 2015-10-06 The Research Foundation Of State University Of New York RNA targeting compounds and methods for making and using same
CA2684798A1 (en) * 2007-04-04 2008-10-16 Novartis Ag Prion elisa
WO2008124098A1 (en) * 2007-04-04 2008-10-16 Novartis Ag Prion assay
CA2696417A1 (en) * 2007-10-02 2009-04-09 Csl Limited Therapeutic antibody purification method and method of use
JP2011511077A (ja) * 2008-02-08 2011-04-07 ノースウエスタン ユニバーシティ 選択的ポリ−ｎ−置換グリシン抗生物質
AU2009243060A1 (en) * 2008-04-30 2009-11-05 Novartis Ag. Assay for pathogenic conformers
WO2010017412A1 (en) * 2008-08-06 2010-02-11 The Regents Of The University Of California Novel biomimetic peptoid polymers
EP2401264A4 (en) * 2009-02-24 2013-08-07 Univ New York PEPTOID OLIGOMERS, PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR USE
AU2010256880B2 (en) 2009-06-02 2015-01-22 Opko Health, Inc. Identification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
WO2011057029A1 (en) * 2009-11-04 2011-05-12 Novartis Ag Positively charged species as binding reagents in the separation of protein aggregates from monomers
US8952127B2 (en) 2010-06-04 2015-02-10 The Regents Of The University Of California Peptoids useful for catalyzing the mineralization of calcium carbonate
WO2013043669A1 (en) * 2011-09-21 2013-03-28 The Board Of Regents Of The University Of Texas System Peptoid compositions for the treatment of alzheimer's disease and polyglutamine expansion disorder
WO2014025785A2 (en) * 2012-08-06 2014-02-13 Trustees Of Boston University Prion protein ligands as therapeutic agents for neurodegenerative disorders
US9764953B2 (en) 2013-03-20 2017-09-19 The Regents Of The University Of California Peptoids useful for the mineralization of apatite
WO2016145286A1 (en) * 2015-03-11 2016-09-15 Lumos Pharma, Inc. Synthesis of cyclocreatine and analogs thereof
CA3001065A1 (en) 2015-10-14 2017-04-20 Xiaoxi WEI Compositions and methods for reducing ice crystal formation
EP3426673B1 (en) * 2016-03-09 2021-05-05 Mike-Ann, LLC Peptoid affinity ligands
JP7212373B2 (ja) * 2017-04-12 2023-01-25 エックス－サーマ インコーポレイテッド 新規ペプトイドポリマーおよび使用方法
JP7495934B2 (ja) 2018-12-10 2024-06-05 プロビビ インコーポレイテッド 共役ジエンフェロモンおよび関連化合物の合成方法

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4806627A (en) 1987-05-29 1989-02-21 Research Foundation Of Mental Hygiene Inc. Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins
US6075121A (en) 1990-05-15 2000-06-13 Chiron Corporation Modified peptide and peptide libraries with protease resistance, derivatives thereof and methods of producing and screening such
IE66205B1 (en) * 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
DE69132470D1 (de) 1990-08-06 2000-12-21 Chiron Corp Verfahren zum nachweis von cytokinkonvertasehemmern
DK0616613T3 (da) 1991-12-03 1999-09-27 Proteus Molecular Design Fragmenter af prionprotein
WO1993023432A1 (en) 1992-05-15 1993-11-25 New York University Soluble prion polypeptides, and methods for detecting and purifying thereof
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
EP1258492A1 (en) 1992-09-24 2002-11-20 Chiron Corporation N-substituted oligomers and methods for their synthesis, e.g. polyglycine bearing nucleic acid bases
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
DE69632056T2 (de) 1995-09-14 2004-12-30 The Regents Of The University Of California, Oakland Für natives prp-sc spezifische antikörper
US5750361A (en) 1995-11-02 1998-05-12 The Regents Of The University Of California Formation and use of prion protein (PRP) complexes
US5695005A (en) 1995-12-28 1997-12-09 Chen; Chia-Hsien Fluid dynamic crossflow cooling tower
BR9708421A (pt) 1996-04-03 1999-08-03 Stichting Inst Dierhouderij Processo para a deteccão de doenca provocada por prions teste diagnostico ou kit de teste e uso do processo
US6586193B2 (en) 1996-04-25 2003-07-01 Genicon Sciences Corporation Analyte assay using particulate labels
DE69725878T2 (de) 1996-08-13 2004-07-29 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzungen zur polynukleotidabgabe
NZ333518A (en) 1997-02-06 2001-06-29 Enfer Technology Ltd Immunological assay for spongiform encephalopathies (TSE)
EP0861900A1 (en) 1997-02-21 1998-09-02 Erziehungsdirektion Of The Canton Zurich Immunological detection of prions
US7005295B1 (en) 1997-04-16 2006-02-28 Wyeth β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6787319B2 (en) 1997-04-16 2004-09-07 American Home Products Corp. β-amyloid peptide-binding proteins and polynucleotides encoding the same
ATE437887T1 (de) 1997-04-28 2009-08-15 Novartis Vaccines & Diagnostic Vorrichtung zur herstellung von oligomeren, insbesondere peptoiden, mit rückführung der reagenzien
DE19741607A1 (de) 1997-09-20 1999-03-25 Prionics Ag Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen
US6165784A (en) 1997-10-14 2000-12-26 The United States Of America As Represented By The Secretary Of Agriculture Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies
WO1999053036A2 (en) 1998-04-14 1999-10-21 Sugen, Inc. Ste20-related protein kinases
US6211149B1 (en) 1998-08-03 2001-04-03 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors of formation of protease resistant prion protein
US6528269B1 (en) 1998-06-22 2003-03-04 Case Western Reserve University Immunological agents specific for prion protein (PRP)
FI982480A0 (fi) 1998-11-17 1998-11-17 Wallac Oy Immunomääritys nisäkkäiden tarttuvan spongiomuotoisen aivotaudin määrittämiseksi
JP5122705B2 (ja) 1999-01-25 2013-01-16 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患における異常型タンパク質凝集の迅速かつ高感度の検出
US6551843B1 (en) 1999-01-29 2003-04-22 Immunivest Corporation Methods for enhancing binding interactions between members of specific binding pairs
HK1048955A1 (zh) 1999-06-23 2003-04-25 Idexx Laboratories, Inc. 朊病毒蛋白肽及其应用
US6261790B1 (en) 1999-07-15 2001-07-17 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies
JP2003506327A (ja) 1999-07-27 2003-02-18 インペリアル・カレッジ・イノベイションズ・リミテッド 疾患の診断および治療に使用できる生物学的物質および方法
JP2003514773A (ja) 1999-09-28 2003-04-22 ウニヴェルジテート チューリッヒ 血清及び血漿中のプリオン結合活性を有する因子並びに伝染性海綿状脳障害を検出するための薬剤
FR2801106B1 (fr) 1999-11-12 2007-10-05 Commissariat Energie Atomique Procede de diagnostic d'une esst provoquee par une souche d'atnc dans un echantillon biologique et son utilisation dans le diagnostic differentiel des differentes souches d'atnc
EP1267904A4 (en) 2000-02-16 2006-02-08 Univ Northwestern POLYPEPTOIDE PULMONARY SURFACTANTS
CA2405568A1 (en) 2000-04-05 2001-10-18 North Carolina State University Prion-binding peptidic ligands and methods of using same
WO2001097785A2 (en) 2000-06-20 2001-12-27 Caprion Pharmaceuticals Inc. Basic copolymers for the treatment of prion-related-disease
EE05675B1 (et) 2000-07-07 2013-08-15 Applied Research Systems Ars Holding N.V. Meetod konformse haiguse diagnoosimiseks v?i tuvastamiseks, selleks vajalik katsemenetlus, reaktiivikomplekt ning seade
US6537548B1 (en) 2000-07-27 2003-03-25 The Regents Of The University Of California Antibodies specific for ungulate PrP
US20030092613A1 (en) 2000-08-14 2003-05-15 Lee Daniel H. S. Alpha7 nicotinic receptor peptides as ligands for beta amyloid peptides
US7422861B2 (en) 2000-12-23 2008-09-09 Novartis Vaccines And Diagnostics, Inc. Oligonucleotide transfection screening method
GB0103508D0 (en) 2001-02-13 2001-03-28 Univ Dundee Screening method and agents
US20050026165A1 (en) 2001-05-31 2005-02-03 Cindy Orser Detection of conformationally altered proteins and prions
MXPA03011000A (es) 2001-05-31 2004-02-27 Arete Associates Metodo de sensor de proteinas deformadas.
US7105221B2 (en) 2001-07-19 2006-09-12 Toray Industries, Inc. Circuit board, laminated member for circuit board, and method for making laminated member for circuit board
US7479482B2 (en) 2001-11-21 2009-01-20 New York University Synthetic immunogenic but non-deposit-forming polypeptides and peptides homologous to amyloid β, prion protein, amylin, α-synuclein, or polyglutamine repeats for induction of an immune response thereto
JP2005514385A (ja) 2001-12-10 2005-05-19 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ プリオン阻害ペプチド及びその誘導体
US20040052928A1 (en) 2002-09-06 2004-03-18 Ehud Gazit Peptides and methods using same for diagnosing and treating amyloid-associated diseases
WO2003066003A2 (en) * 2002-02-07 2003-08-14 Massachusetts Institute Of Technology Anti-pathogen treatements
US7659076B2 (en) 2002-02-28 2010-02-09 Microsens Biophage Limited Binding of pathological forms of prion proteins
ATE544780T1 (de) 2002-04-09 2012-02-15 Scripps Research Inst Hybrid-polypeptide mit eingefügten sequenzmotiven und ihre verwendungen
US20040208919A1 (en) 2002-06-13 2004-10-21 Nicolau Yves C. Vaccination against prion diseases
DE10230141B4 (de) 2002-07-04 2004-07-15 Priontype Gmbh Verfahren und Kit zur Anreicherung und zum Nachweis von veränderten Prion-Proteinen (PrPSc)
EP1382971A1 (en) 2002-07-17 2004-01-21 Pepscan Systems B.V. Detection of prion disease
AU2003257398A1 (en) 2002-08-23 2004-03-11 Copenhagen Biotech Assets Aps Composite peptide compounds for diagnosis and treatment of diseases caused by prion proteins
US20040072236A1 (en) 2002-09-27 2004-04-15 Neil Cashman PrPSc -interacting molecules and uses thereof
DE03799419T1 (de) 2002-10-10 2005-04-07 The Regents Of The University Of California, Oakland Verwendung monoklonaler antikörper zur unterscheidung von proteinkonformationsisoformen
DE60219215T2 (de) 2002-10-23 2008-01-03 Centre For Research And Technology Hellas/Intitute Of Agrobiotechnology In.A, Thermi Prionen-bindende peptidsequenzen
AU2002352042A1 (en) 2002-11-18 2004-06-15 Prionics Ag Method for the detection of prpsc
ES2375958T3 (es) 2002-12-03 2012-03-07 Pathogen Removal And Diagnostic Technologies, Inc. Ligandos de prote�?nas priones y procedimientos de uso.
EP1457500A1 (en) 2003-03-14 2004-09-15 University of Zurich Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalophathies
NZ543371A (en) 2003-04-04 2008-04-30 Pathogen Removal And Diagnosti Prion protein binding materials and methods of use
WO2004092197A2 (en) 2003-04-07 2004-10-28 The Regents Of The University Of California Amyloid-specific peptides and uses thereof
CA2522483A1 (en) 2003-04-14 2004-10-28 Julia T. Lathrop Method for identifying ligands specific for structural isoforms of proteins
MXPA06001588A (es) 2003-08-13 2006-08-25 Chiron Corp Reactivos de peptido especificos de prion.
US20060035242A1 (en) 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
JP3910569B2 (ja) 2003-08-19 2007-04-25 独立行政法人科学技術振興機構 アミロイドβ蛋白質のアミロイド線維化を増幅するための試薬
WO2005060697A2 (en) * 2003-12-19 2005-07-07 Chiron Corporation Cell transfecting formulations of small interfering rna, related compositions and methods of making and use
SE0400274D0 (sv) 2004-02-09 2004-02-09 Affibody Ab New polypeptide
JP4773697B2 (ja) 2004-06-30 2011-09-14 ルネサスエレクトロニクス株式会社 Ｓｏｉ基板およびその製造方法ならびに半導体装置
DE102004043782A1 (de) 2004-09-08 2006-03-09 Heinrich-Heine-Universität Düsseldorf Polypeptide und Verfahren zur spezifischen Bindung von Prionen
US20060057671A1 (en) 2004-09-10 2006-03-16 Orser Cindy S Immobilized probes and methods of detecting conformationally altered prion proteins
US7482172B2 (en) 2005-09-19 2009-01-27 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
AU2005209592B2 (en) 2004-09-30 2012-07-12 Ortho-Clinical Diagnostics, Inc. Peptides for discrimination of prions
JP5162250B2 (ja) 2005-01-13 2013-03-13 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド プリオン特異的ペプチド試薬を使用するｅｌｉｓａアッセイ
WO2006076497A2 (en) 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Osplation of pathogenic prions
WO2006088823A2 (en) 2005-02-15 2006-08-24 Adlyfe, Inc. Method for detecting misfolded proteins and prions
GB0503434D0 (en) 2005-02-18 2005-03-30 Senexis Ltd Amyloid-binding peptides, analogues and uses thereof
US7834144B2 (en) 2005-09-09 2010-11-16 Novartis Ag Prion-specific peptoid reagents
WO2007145589A1 (en) 2006-06-15 2007-12-21 Per Arvidsson Peptides that are capable of binding to amyloid-beta peptide.
CN101802609A (zh) 2006-07-28 2010-08-11 阿德利夫股份有限公司 用于诊断和治疗的肽探针
US9217036B2 (en) 2007-04-26 2015-12-22 Yale University Prion protein as a receptor for amyloid-β oligomers

Also Published As

Publication number Publication date
JP2009507833A (ja) 2009-02-26
IL189992A0 (en) 2008-08-07
AU2006287299B2 (en) 2012-08-23
EP1931695A1 (en) 2008-06-18
ES2404940T3 (es) 2013-05-29
BRPI0615618A2 (pt) 2011-05-24
ZA200802186B (en) 2008-12-31
JP2012162571A (ja) 2012-08-30
EP1931695B1 (en) 2013-04-10
US20120027677A1 (en) 2012-02-02
KR20080048527A (ko) 2008-06-02
EP2383281A3 (en) 2012-01-04
AU2006287299A1 (en) 2007-03-15
DK1931695T3 (da) 2013-07-01
NZ566020A (en) 2012-08-31
CA2621767A1 (en) 2007-03-15
EP2383281A2 (en) 2011-11-02
US7834144B2 (en) 2010-11-16
CN101356186A (zh) 2009-01-28
US20070087972A1 (en) 2007-04-19
JP5209477B2 (ja) 2013-06-12
WO2007030804A1 (en) 2007-03-15

Similar Documents

Publication Publication Date Title
NZ594844A (en) Prion-specific peptoid reagents
AU2002248147B2 (en) Hepatitis C tripeptide inhibitors
US5700827A (en) Amino acid derivatives, processes for the manufacture thereof and pharmaceutical compositions (II) containing these compounds
CN1312817A (zh) 截尾海兔肽15衍生物
CZ296915B6 (cs) Slouceniny inhibující proteázy retroviru
CA2459449A1 (en) Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
JP7641895B2 (ja) 液相ペプチド合成のための方法およびその保護戦略
EP1149843A1 (en) Substituted phenethylamine derivatives
ES2359302T3 (es) Un proceso para preparar un derivado de fenilalanina e intermedios de los mismos.
TW209870B (enExample)
EP1009770A1 (en) Peptides containing an arginine mimetic for the treatment of bone metabolic disorders, their production, and drugs containing these compounds
Schmittberger et al. Synthesis of the palmitoylated and prenylated C-terminal lipopeptides of the human R-and N-Ras proteins
EP0640618B1 (de) Tetrahydronaphthalin-Peptidderivate
EP0758328A1 (en) Anti-cancer compounds containing cyclopentaquinazoline ring
DK0918795T3 (da) Antiangiogene lægemidler til behandling af cancer, arthritis og retinopati
US4341707A (en) Imido carbonate compound, production thereof and uses thereof as reagent for forming active ester of amino acids
AU614558B2 (en) N-substituted mercaptopropanamide derivatives
JP5475832B2 (ja) Ｎ−（ｎ’−置換グリシル）−２−シアノピロリジン誘導体の製法
El Khatib et al. Solution-phase synthesis of chiral O-acyl isodipeptides
EP4077353B1 (en) Synthesis of amanin and its derivatives
US5807979A (en) Synthetic, three-dimensionally stabilized polypeptide mimics of HIV
Kong et al. Aspartimide Formation and Its Prevention in Fmoc Chemistry Solid Phase Peptide Synthesis
DE69905397T2 (de) Selektive inhibitoren des mmp-12
US20030191053A1 (en) Cyclic peptide derivative
HU194558B (en) Process for producing /3s/-3-square bracket opened-figure bracket opened-/2-amino-4-thiazolyl/-/1-carboxy-1-methyl-etoxy-imino/-acetyl-figure bracket closed-amino-square bracket closed-4-alkyl-2-oxo-1-azetidinyl-sulfonic acid

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 SEP 2016 BY FB RICE

Effective date: 20130823

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 08 SEP 2013 BY FB RICE

Effective date: 20130731

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 890887, NOVARTIS AG, LICHTSTRASSE 35, CH-4056 BASEL, CH

Effective date: 20140409

LAPS Patent lapsed